Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Phase 2 Open-Label Study of Oral Dapansutrile in Schnitzler's Syndrome
2017-003282-98Phase 2Terminated
- Sponsor
- Olatec Therapeutics LLC
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapansutrile in Schnitzler syndrome, sponsored by Olatec Therapeutics LLC. Started Jan 2018; status: terminated.
02
Drugs
dapansutrile
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on 2017-003282-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003282-98.